title: Should prophylaxis for Pneumocystis jirovecii pneumonia be considered in patients with a CD4+ count higher than 200 cells/μl?
authors.affiliation: aInfectious Disease Unit, Baruch-Padeh Medical Center, Poriya bFaculty of Medicine, Bar Ilan University, Galilee cClinical Microbiology Laboratory, Baruch-Padeh Medical Center, Poriya dThe Institute of Clinical Immunology, Allergy and AIDS, Rambam Medical Center eRappaport Faculty of Medicine, Technion, Haifa, Israel.
authors.forename: Orna
authors.initials: O
authors.lastname: Nitzan
authors.forename: Avi
authors.initials: A
authors.lastname: Peretz
authors.forename: Nina
authors.initials: N
authors.lastname: Pastukh
authors.forename: Margalit
authors.initials: M
authors.lastname: Lorber
mesh_terms: D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage*; D018791:CD4 Lymphocyte Count; D018890:Chemoprevention / Q000379:methods*; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000473:pathology*; D006801:Humans; D045363:Pneumocystis carinii / Q000187:drug effects*; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control*
chemical_list: D000935:Antifungal Agents